Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | active not recruiting | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 |
| clinicaltrials |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms(LIMBER) | active not recruiting | Phase 1 | 140 | Incyte CorporationINDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT02051257 | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 51 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04980404 | Inqovi Maintenance Therapy in Myeloid Neoplasms | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04261855 | Targeted Therapy and Avelumab in Merkel Cell Carcinoma(GoTHAM) | active not recruiting | Phase 1 / Phase 2 | 19 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06767046 | KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | active not recruiting | Phase 1 | 8 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05680922 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 41 | Legend Biotech USA IncINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491159 | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | active not recruiting | Phase 1 / Phase 2 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02298348 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma(N2013-02) | active not recruiting | Phase 1 | 18 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT02573896 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | active not recruiting | Phase 1 | 13 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT02852655 | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | active not recruiting | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04419532 | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | Mar 20, 2026 | clinicaltrials |
| NCT02789228 | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors(REST) | active not recruiting | Phase 1 | 28 | Children's National Research InstituteOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | active not recruiting | Phase 1 | 54 | Fate TherapeuticsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05610891 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | active not recruiting | Phase 1 | 50 | Cellectar Biosciences, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03742245 | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | active not recruiting | Phase 1 | 28 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | active not recruiting | Phase 1 / Phase 2 | 48 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03749187 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas(PNOC017) | active not recruiting | Phase 1 | 78 | University of California, San FranciscoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04004442 | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma(COAXIN) | active not recruiting | Phase 1 | 19 | University of OklahomaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05364073 | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | active not recruiting | Phase 1 | 160 | ArriVent BioPharma, Inc.INDUSTRY | 11 | Mar 13, 2026 | clinicaltrials |
| NCT04897022 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05382364 | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | active not recruiting | Phase 1 | 25 | PfizerINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | active not recruiting | Phase 1 | 60 | Institut de Recherches Internationales ServierOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2026source: clinicaltrials